Diabetic Foot Ulcer
Conditions
Brief summary
The present clinical trial is designed to assess the effectiveness of BioChaperone PDGF-BB applied at 4 µg/cm² every other day for up to 20 weeks and associated to Standard of Care as compared to Standard of Care alone for the treatment of neuropathic and neurovascular diabetic foot ulcers.(In order to ensure the double-blinding of the treatments, a sterile normal saline solution presented in the same multi-dose spray vials than BioChaperone PDGF-BB will be applied on patients of the control group).
Interventions
DRUGBioChaperone PDGF-BB
OTHERStandard of Care
Sponsors
Virchow Group
Adocia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women aged 18 years old or older, with type 1 or 2 diabetes mellitus * Patient with a single ulcer on the treated feet * Patient able and willing to provide informed consent * Patient able and willing to comply with protocol visits and procedure * Patient willing to use an off-loading method during the whole duration of the study * Full-thickness plantar, lateral or dorsal ulcer of the extremity (below the malleolus), excluding inter-digits ulcer (web spaces), extending through the epidermis and dermis, but not involving bone, tendons, ligaments or muscles (grade IA as defined by University of Texas Diabetic Wound Classification or Grade 1 according to Wagner classification) * Chronic ulcer of at least six weeks despite appropriate wound care * Ulcer area measured with the formula Length x Width x 0.8 following sharp debridement, of 1 to 10 cm², both inclusive * Well controlled infection or cellulitis (systemic antibiotherapy) before Baseline Visit * Peripheral neuropathy as assessed by Semmes- Weinstein monofilament test or by the bio esthesimeter (vibration perception threshold). * Ankle brachial pressure index \> 0.60 and \<1.3 * Women surgically sterile, post-menopausal, or agree to practice adequate contraception and have a negative pregnancy test at screening. Non-nursing
Exclusion criteria
* Inter digit ulcers * Ulcer of other cause or origin: electrical, chemical or radiation insult, bedsores, vascular ulcer or Charcot deformities ulcers * Charcot foot. * Wound originated from amputation bed * Active ulcer infection assessed by clinical examination and radiography if necessary. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement and controlled by standard wound care. * Active osteomyelitis affecting the area of the target ulcer * Poorly controlled diabetes (uncontrolled glycemia: HbA1c% \>= 10%), renal failure (serum creatinine \> 3.0 mg/dL), poor nutritional status (albumin \< 3.0 g/dL or total protein \< 6.5 g/dL) * Known connective tissue or malignant disease * Concomitant treatment with corticosteroids, immunosuppressive agents, radiation therapy, or anticancer chemotherapy * Use of investigational drug/device or growth factor within 30 days * Topical application of any advance wound care on this wound (antiseptics, antibiotics, debriders, enzyme) within 7 days * Vascular reconstruction within 8 weeks * Patients expected to be noncompliant with the protocol (not available for the duration of the trial, treatment or wound care compliance), or felt to be unsuitable by the Investigator for any other reason. * A history of severe cerebrovascular events
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of complete wound closure. | 20 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Time to achieve complete wound closure. | 20 weeks |
| Percentage reduction in total ulcer surface area at each visit. | 20 weeks |
| Incidence of complete wound healing | 10 weeks |
| Number of ulcer recurrence observed 12 weeks after wound healing. | 32 weeks |
| Treatment emergent adverse events. | 52 weeks |
Countries
India
Outcome results
None listed